Cellectar Biosciences (CLRB) Projected to Announce Earnings on Thursday

Cellectar Biosciences (NASDAQ:CLRB) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Cellectar Biosciences to announce earnings of ($0.55) per share and revenue of $12.00 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($1.88) by $0.55. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cellectar Biosciences Stock Down 1.6%

NASDAQ:CLRB opened at $2.52 on Thursday. The stock has a fifty day simple moving average of $2.60 and a 200 day simple moving average of $2.91. The firm has a market capitalization of $20.13 million, a price-to-earnings ratio of -0.38 and a beta of 0.55. Cellectar Biosciences has a 1-year low of $2.20 and a 1-year high of $6.52.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Friday, July 17th. Wall Street Zen upgraded Cellectar Biosciences to a “hold” rating in a research report on Saturday, June 20th. LADENBURG THALM/SH SH started coverage on Cellectar Biosciences in a report on Friday, May 15th. They issued a “buy” rating on the stock. Roth Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. Finally, Brookline Capital Markets upgraded shares of Cellectar Biosciences to a “strong-buy” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cellectar Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Investors Weigh In On Cellectar Biosciences

Large investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in Cellectar Biosciences in the fourth quarter worth approximately $36,000. Bank of America Corp DE lifted its stake in Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 41,704 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Cellectar Biosciences in the third quarter worth approximately $73,000. Geode Capital Management LLC grew its position in Cellectar Biosciences by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 3,744 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Cellectar Biosciences during the 3rd quarter worth $104,000. Institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.